Literature DB >> 14979960

Case of thymic parathyroid carcinoma in a haemodialysis patient: application of tumour chemosensitivity testing.

I A Srouji1, A Resouly, I A Cree.   

Abstract

Parathyroid carcinoma is a rare tumour, which is often difficult to diagnose. This is especially true in patients with pre-existing tertiary hyperparathyroidism of end-stage renal disease. A case is presented of parathyroid carcinoma in a haemodialysis patient with unusual thymic involvement. After demonstrating the difficulty in pre-operative diagnosis and risk of recurrence, the importance of non-surgical treatment options is discussed and the investigation of individual tumour chemosensitivity is introduced, which is new to this type of cancer.

Entities:  

Mesh:

Year:  2004        PMID: 14979960     DOI: 10.1258/002221504772784685

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  4 in total

1.  Mediastinal parathyroid carcinoma presenting with severe skeletal manifestations.

Authors:  Tuck Y Yong; Jordan Y Z Li
Journal:  J Bone Miner Metab       Date:  2010-03-18       Impact factor: 2.626

2.  Parathyroid Carcinoma in the Setting of Tertiary Hyperparathyroidism: Case Report and Review of the Literature.

Authors:  Federico Cappellacci; Fabio Medas; Gian Luigi Canu; Maria Letizia Lai; Giovanni Conzo; Enrico Erdas; Pietro Giorgio Calò
Journal:  Case Rep Endocrinol       Date:  2020-12-02

Review 3.  Benefits of functional assays in personalized cancer medicine: more than just a proof-of-concept.

Authors:  Christophe Bounaix Morand du Puch; Mathieu Vanderstraete; Stéphanie Giraud; Christophe Lautrette; Niki Christou; Muriel Mathonnet
Journal:  Theranostics       Date:  2021-09-21       Impact factor: 11.556

Review 4.  Persistent Hypercalcemia Crisis and Recurrent Acute Pancreatitis Due to Multiple Ectopic Parathyroid Carcinomas: Case Report and Literature Review of Mediastinal Parathyroid Carcinoma.

Authors:  Ruizhi Jiajue; An Song; Ou Wang; Wei Li
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-10       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.